{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:43:42Z","timestamp":1785577422399,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12094-017-1684-4","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T04:02:13Z","timestamp":1496376133000},"page":"1454-1461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain"],"prefix":"10.1007","volume":"19","author":[{"given":"G.","family":"Lopez-Vivanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Salas-Cansado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-6790","authenticated-orcid":false,"given":"B.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De la Haba-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"key":"1684_CR1","unstructured":"EMA\u2014European Medicines Agency. Summary of Product Characteristics Herceptin. 2010. Available at: \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000278\/WC500074922.pdf\n                        \n                    . Accessed: 27 July 2016."},{"issue":"9","key":"1684_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869\u201378. doi:\n                        10.1016\/S1470-2045(12)70329-7\n                        \n                    .","journal-title":"Lancet Oncol"},{"key":"1684_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/1472-6963-12-370","volume":"12","author":"GA Shinder","year":"2012","unstructured":"Shinder GA, Paradis PE, Posman M, Mishagina N, Guay MP, Linardos D, et al. Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada\u2013a time and motion study. BMC Health Serv Res. 2012;12:370. doi:\n                        10.1186\/1472-6963-12-370\n                        \n                    .","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"1684_CR4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00002820-200511000-00011","volume":"28","author":"A Colombo","year":"2005","unstructured":"Colombo A, Solberg B, Vanderhoeft E, Ramsay G, Schouten HC. Measurement of nursing care time of specific interventions on a hematology-oncology unit related to diagnostic categories. Cancer Nurs. 2005;28(6):476\u201380.","journal-title":"Cancer Nurs"},{"issue":"1","key":"1684_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jjco\/hyq152","volume":"41","author":"S Mache","year":"2011","unstructured":"Mache S, Sch\u00f6ffel N, Kusma B, Vitzthum K, Klapp BF, Groneberg DA. Cancer care and residents\u2019 working hours in oncology and hematology departments: an observational real-time study in German hospitals. Jpn J Clin Oncol. 2011;41(1):81\u20136. doi:\n                        10.1093\/jjco\/hyq152\n                        \n                    .","journal-title":"Jpn J Clin Oncol"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1191\/1078155201jp077oa","volume":"7","author":"G Dranitsaris","year":"2001","unstructured":"Dranitsaris G, Castel L, Baladi JF, Schulman KA. Zoledronic acid versus pamidronate as palliative therapy in cancer patients: a Canadian time and motion analysis. J Oncol Pharm Practice. 2001;7:27\u201333. doi:\n                        10.1191\/1078155201jp077oa\n                        \n                    .","journal-title":"J Oncol Pharm Practice"},{"issue":"10","key":"1684_CR7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2165\/00044011-200626100-00006","volume":"26","author":"KR Meehan","year":"2006","unstructured":"Meehan KR, Tchekmedyian NS, Smith RE, Kallich J. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa. Clin Drug Investig. 2006;26(10):593\u2013601.","journal-title":"Clin Drug Investig."},{"issue":"11","key":"1684_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1548-5315(11)70357-6","volume":"6","author":"A Oglesby","year":"2009","unstructured":"Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Commun Oncol. 2009;6(11):494\u2013502. doi:\n                        10.1016\/S1548-5315(11)70357-6\n                        \n                    .","journal-title":"Commun Oncol"},{"issue":"5","key":"1684_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40261-013-0078-9","volume":"33","author":"JF Reitan","year":"2013","unstructured":"Reitan JF, van Breda A, Corey-Lisle PK, Shreay S, Cong Z, Legg J. Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices. Clin Drug Investig. 2013;33(5):383\u20139. doi:\n                        10.1007\/s40261-013-0078-9\n                        \n                    .","journal-title":"Clin Drug Investig"},{"issue":"3","key":"1684_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cam4.573","volume":"5","author":"E Cock De","year":"2016","unstructured":"De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389\u201397. doi:\n                        10.1002\/cam4.573\n                        \n                    .","journal-title":"Cancer Med"},{"key":"1684_CR11","doi-asserted-by":"crossref","unstructured":"Pivot X, Knoop A, Curigliano G, Barrett-Lee P, Lichinitser M, Mueller V, et al. PrefHer: A clinical trial to evaluate patient preference for trastuzumab administered subcutaneously or intravenously in patients with HER2-positive early breast cancer. Presented at the 8th European Breast Cancer Conference, March 21\u201324, 2012, Vienna, Austria","DOI":"10.1016\/S0959-8049(12)70510-5"},{"issue":"10","key":"1684_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, M\u00fcller V, Barrett-Lee P, Verma S, Knoop A, et al. PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962\u201370. doi:\n                        10.1016\/S1470-2045(13)70383-8\n                        \n                    .","journal-title":"Lancet Oncol"},{"key":"1684_CR13","unstructured":"Curtis L. Unit costs of Health and Social Care 2012. Personal Social Services Research Unit (PSSRU). Available at: \n                        http:\/\/www.pssru.ac.uk\n                        \n                    ."},{"key":"1684_CR14","unstructured":"Comunidad Aut\u00f3noma de Arag\u00f3n. Retribuciones correspondientes al a\u00f1o 2011 del personal del Servicio Aragon\u00e9s de Salud al que resulta de aplicaci\u00f3n el sistema retributivo establecido en la ley 55\/2003, del estatuto marco del personal estatutario de los servicios de salud. 2011."},{"key":"1684_CR15","unstructured":"Generalitat Valenciana. 2012. Retribuciones correspondientes al a\u00f1o 2012 de la Agencia Valenciana de Salud. 2012."},{"key":"1684_CR16","unstructured":"National Statistics Institute (INE). Spanish Statistical Office. 2016. Available at: \n                        www.ine.es\n                        \n                    . Accessed: 27 July 2016."},{"key":"1684_CR17","unstructured":"General Council of the Association of Official Pharmacists. General Council of the Association of Official Pharmacists Database: Bot PLUS 2.0. Available at: \n                        https:\/\/botplusweb.portalfarma.com\/\n                        \n                    . Accessed: 27 July 2016."},{"key":"1684_CR18","unstructured":"Garc\u00eda P\u00e9rez L, Rodr\u00edguez Huerta MD, Serrano Aguilar P. Informe sobre la seguridad, la efectividad e impacto presupuestario de la soluci\u00f3n de heparina para el mantenimiento del cat\u00e9ter venoso perif\u00e9rico. 2013. Available at: \n                        http:\/\/www3.gobiernodecanarias.org\/sanidad\/scs\/content\/59291b67-d5e5-11e3-afe3-adc9cf9775fd\/Informe%20Fibrilin_SESCS%202014.pdf\n                        \n                    . Accessed: 27 July 2016."},{"key":"1684_CR19","unstructured":"Hern\u00e1n Gascue\u00f1a D, Guerra Llamas I, Pereira Feijoo C, Queija Mart\u00ednez L, Vieira H, Guti\u00e9rrez G\u00f3mez JA. An\u00e1lisis de costes: cat\u00e9ter versus FAVI. Available at: \n                        http:\/\/www.revistaseden.org\/files\/1816_h2.pdf\n                        \n                    . Accessed: 27 July 2016."},{"key":"1684_CR20","first-page":"6","volume":"197","author":"M Gaspar Carre\u00f1o","year":"2011","unstructured":"Gaspar Carre\u00f1o M, Arias Pou P, Rodr\u00edguez Berges O, Gamundi MC, Carbonell Tatay F. Revisi\u00f3n sobre el uso de guantes en los hospitales. El Farmac\u00e9utico Hosp. 2011;197:6\u201323.","journal-title":"El Farmac\u00e9utico Hosp"},{"key":"1684_CR21","unstructured":"Servicio Andaluz de Salud (SAS). Hospital Regional de M\u00e1laga. Acuerdo Marco 4001\/2010 para la selecci\u00f3n de material gen\u00e9rico de curas, subgrupo 01.00 del Cat\u00e1logo, adjudicado por Resoluci\u00f3n de la Direcci\u00f3n General de G.E. de 23 de septiembre de 2010."},{"key":"1684_CR22","unstructured":"ASEPEYO. Anexo I. Pliego de Prescripciones t\u00e9cnicas para la contrataci\u00f3n del Suministro de Desinfectantes y Antis\u00e9pticos para Mutua ASEPEYO. 2010."},{"key":"1684_CR23","unstructured":"Comunidad de Madrid. Hospital Universitario de Getafe. Pliego de Prescripciones T\u00e9cnicas para la adquisici\u00f3n de material de infusi\u00f3n intravenosa. Por Expte. PAPC2013-1-6. Available at: \n                        http:\/\/www.madrid.org\/contratos-publicos\/1354184929453\/1109266750213\/1354184932754.pdf\n                        \n                    . Accessed: 28 May 2017."},{"key":"1684_CR24","unstructured":"Gisbert R, Brosa M. Healthcare cost database eSALUD [Internet]. Barcelona: Oblikue Consulting, SL 2015. Available at: \n                        http:\/\/www.oblikue.com\/bddcostes\/\n                        \n                    . Accessed: 27 July 2016."},{"issue":"3","key":"1684_CR25","first-page":"176","volume":"7","author":"K Papadmitriou","year":"2015","unstructured":"Papadmitriou K, Trinh XB, Altintas S, Van Dam PA, Huizing MT, Tjalma WA. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future perspectives. Facts Views Vis Obgyn. 2015;7(3):176\u201380.","journal-title":"Facts Views Vis Obgyn"},{"issue":"3","key":"1684_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bulcan.2015.01.007","volume":"102","author":"V Lieutenant","year":"2015","unstructured":"Lieutenant V, Toulza \u00c9, Pommier M, Lortal-Canguilhem B. Is Herceptin\u00ae (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study. Bull Cancer. 2015;102(3):270\u20136. doi:\n                        10.1016\/j.bulcan.2015.01.007\n                        \n                    .","journal-title":"Bull Cancer"},{"key":"1684_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/CEOR.S85599","volume":"7","author":"RT North","year":"2015","unstructured":"North RT, Harvey VJ, Cox LC, Ryan SN. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015;7:423\u201330. doi:\n                        10.2147\/CEOR.S85599\n                        \n                    .","journal-title":"Clinicoecon Outcomes Res"},{"key":"1684_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4236\/abcr.2013.24022","volume":"2","author":"R Burcombe","year":"2013","unstructured":"Burcombe R, Chan S, Simock R, Samanta K, Percival F, Barrett-Lee P. Subcutaneous Trastuzumab (Herceptin\u00ae): A UK Time and Motion Study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. ABCR. 2013;2:133\u201340. doi:\n                        10.4236\/abcr.2013.24022\n                        \n                    .","journal-title":"ABCR"},{"issue":"6","key":"1684_CR29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0035-1546172","volume":"75","author":"C Jackisch","year":"2015","unstructured":"Jackisch C, M\u00fcller V, Dall P, Neumeister R, Park-Simon TW, Ruf-D\u00f6rdelmann A, et al. Subcutaneous Trastuzumab for HER2-positive breast cancer\u2014evidence and practical experience in 7 german centers. Geburtshilfe Frauenheilkd. 2015;75(6):566\u201373.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"7","key":"1684_CR30","doi-asserted-by":"publisher","first-page":"A823","DOI":"10.1016\/j.jval.2015.09.271","volume":"18","author":"M Romero","year":"2015","unstructured":"Romero M, Acero G, Huerfano LM. An\u00e1lisis de minimizaci\u00f3n de costos del uso de trastuzumab subcut\u00e1neo frente a trastuzumab intravenoso en el tratamiento de c\u00e1ncer de mama temprano en mujeres con HER2 positivo para Venezuela (PCN43). Value Health. 2015;18(7):A823. doi:\n                        10.1016\/j.jval.2015.09.271\n                        \n                    .","journal-title":"Value Health"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1684-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1684-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1684-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T04:15:54Z","timestamp":1511324154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1684-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1684-4","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]}}}